scispace - formally typeset
M

Michael Karin

Researcher at University of California, San Diego

Publications -  753
Citations -  246120

Michael Karin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: IκB kinase & Signal transduction. The author has an hindex of 236, co-authored 704 publications receiving 226485 citations. Previous affiliations of Michael Karin include Sanford-Burnham Institute for Medical Research & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression

TL;DR: The role of NF-kappaB in inflammation-induced tumor growth is investigated in an experimental murine cancer metastasis model and it is found that LPS-induced metastatic growth response in this model depends on both TNFalpha production by host hematopoietic cells and NF- kappaB activation in tumor cells.
Journal ArticleDOI

Control of cell cycle progression by c-Jun is p53 dependent

TL;DR: It is demonstrated that fibroblasts derived from c-jun-/- mouse fetuses exhibit a severe proliferation defect and undergo a prolonged crisis before spontaneous immortalization, and a mechanistic link between c-Jun-dependent mitogenic signaling and cell-cycle regulation is established.
Journal ArticleDOI

Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression

TL;DR: It is found that hypoxia powerfully augmented macrophage-mediated T-cell suppression in vitro in a manner dependent on macrophages expression of HIF-1α, which links the innate immune hypoxic response to tumor progression through induction of T- cell suppression in the tumor microenvironment.
Journal ArticleDOI

Immunity, inflammation, and cancer: an eternal fight between good and evil

TL;DR: This antagonism between inflammation and immunity also affects the outcome of cancer treatment and needs to be considered when designing new therapeutic approaches.